Frontlight ResearchEarly access
CompletedNo phase
RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study
Key facts
- Who runs it
- RxSight, Inc.
- Where
- Alexandria, Brecksville, Chico, Dallas, Fayetteville, Houston, Hurst, Largo, Las Vegas, Mt. Pleasant, Omaha, San Antonio, Sebring, and Sioux Falls, United StatesSee the 14 sites
- Trial code
- Status
- Completed
- People taking part
- 500 people enrolled
- Started
- 3 Dec 2021
- Ended
- 16 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Light Adjustable lens (LAL) and Light Delivery Device (LDD)
- Control IOL
- Record updated
- 20 April 2025
Who can take part
- Age
- 40 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Must sign a written Informed Consent form and be willing to undergo cataract surgery for the implantation of an IOL with random assignment to either the RxSight LAL or the monofocal control IOL
- Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed
- Willing and able to comply with the requirements for study specific procedures and visits
- Able to complete a written questionnaire in English
Who cannot take part
- Previous intraocular surgery in either eye. Eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus
- Subjects taking systemic medication that may increase sensitivity to UV light
- Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen
- Pre-existing macular disease in either eye
- History of uveitis in either eye
- History of ocular herpes simplex virus in either eye
- Patients with sufficiently dense cataracts that preclude examination of the macula in either eye
- Evidence of ectasia in either eye
Where in United States
- Vance Thompson VisionAlexandria, United States
- Cleveland Eye ClinicBrecksville, United States
- Reeve Woods Eye CenterChico, United States
- Key-Whitman Eye CenterDallas, United States
- Vold VisionFayetteville, United States
- Slade & Baker VisionHouston, United States
- Texas Eye Research CenterHurst, United States
- The Eye Institute of West FloridaLargo, United States
- Center for SightLas Vegas, United States
- Carolina Eyecare Physicians LLCMt. Pleasant, United States
- Vance Thompson VisionOmaha, United States
- Focal Point VisionSan Antonio, United States
- Newsom EyeSebring, United States
- Vance Thompson Vision ClinicSioux Falls, United States
About the trial
What the trial wants to find out
The primary objective of this study is to conduct a post-approval study which compares the LAL to a monofocal control IOL for safety outcomes.
The 2 groups in the trial
- Light adjustable lens (LAL) and Light Delivery Device (LDD)Treatment being tested
- Control IOLExisting treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study
- Publications
- Clinical outcomes of patients bilaterally implanted with the light adjustable lens: results of a phase IV clinical registry.Journal of cataract and refractive surgery, 2026
- Record updated
- 20 April 2025